Sequoia Financial Advisors LLC Buys 491 Shares of Revvity, Inc. (NYSE:RVTY)

Sequoia Financial Advisors LLC grew its stake in shares of Revvity, Inc. (NYSE:RVTY) by 2.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 23,865 shares of the company’s stock after buying an additional 491 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Revvity were worth $3,049,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Janus Henderson Group PLC lifted its holdings in shares of Revvity by 3.9% during the first quarter. Janus Henderson Group PLC now owns 5,664,528 shares of the company’s stock worth $594,769,000 after purchasing an additional 210,100 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Revvity by 18.5% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,126,271 shares of the company’s stock worth $223,258,000 after buying an additional 332,632 shares during the period. EdgePoint Investment Group Inc. acquired a new position in Revvity during the 2nd quarter worth about $209,221,000. Dimensional Fund Advisors LP grew its position in shares of Revvity by 5.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,149,122 shares of the company’s stock valued at $120,506,000 after buying an additional 57,656 shares during the last quarter. Finally, Ceredex Value Advisors LLC increased its stake in shares of Revvity by 2.2% in the second quarter. Ceredex Value Advisors LLC now owns 1,094,938 shares of the company’s stock valued at $114,815,000 after buying an additional 23,318 shares during the period. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RVTY. Barclays upgraded Revvity from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $125.00 to $140.00 in a report on Tuesday, October 15th. Jefferies Financial Group increased their price objective on shares of Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research report on Monday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Revvity from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Tuesday, July 30th. Leerink Partnrs upgraded Revvity to a “strong-buy” rating in a report on Monday, July 8th. Finally, Citigroup boosted their price objective on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $127.20.

Insider Activity

In related news, insider Tajinder S. Vohra sold 2,153 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $122.09, for a total value of $262,859.77. Following the transaction, the insider now owns 23,960 shares in the company, valued at approximately $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Revvity news, insider Joel S. Goldberg sold 3,500 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the completion of the transaction, the insider now owns 33,400 shares in the company, valued at $3,936,524. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Tajinder S. Vohra sold 2,153 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the sale, the insider now directly owns 23,960 shares in the company, valued at approximately $2,925,276.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,807 shares of company stock valued at $937,576 in the last three months. Company insiders own 0.60% of the company’s stock.

Revvity Stock Down 0.2 %

RVTY opened at $118.50 on Thursday. Revvity, Inc. has a fifty-two week low of $79.50 and a fifty-two week high of $128.15. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.98. The company’s 50-day moving average is $121.66 and its 200 day moving average is $113.41. The firm has a market capitalization of $14.62 billion, a P/E ratio of 97.93, a PEG ratio of 3.35 and a beta of 1.05.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. The firm had revenue of $691.70 million for the quarter, compared to the consensus estimate of $690.33 million. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.21 EPS. Research analysts expect that Revvity, Inc. will post 4.75 earnings per share for the current fiscal year.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.